These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 2968265

  • 1. Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study.
    Valavaara R, Pyrhönen S, Heikkinen M, Rissanen P, Blanco G, Thölix E, Nordman E, Taskinen P, Holsti L, Hajba A.
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):785-90. PubMed ID: 2968265
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of toremifene in breast cancer patients. A phase II study.
    Valavaara R, Pyrhönen S, Heikkinen M, Rissanen P, Blanco G, Nordman E, Taskinen P, Holsti LR, Hajba A.
    J Steroid Biochem; 1990 Jun 22; 36(3):229-31. PubMed ID: 2142240
    [Abstract] [Full Text] [Related]

  • 3. Toremifene, a new antiestrogenic compound in the treatment of metastatic mammary cancer. A phase II study.
    Gundersen S.
    J Steroid Biochem; 1990 Jun 22; 36(3):233-4. PubMed ID: 2142241
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Treatment of advanced breast cancer with 20 mg toremifene, a phase II study. Preliminary communication.
    Pyrhönen S, Valavaara R, Heikkinen M, Rissanen P, Blanco G, Nordman E, Holsti LR, Hajba A.
    J Steroid Biochem; 1990 Jun 22; 36(3):227-8. PubMed ID: 2142239
    [Abstract] [Full Text] [Related]

  • 6. Phase II clinical study of high-dose toremifene in patients with advanced breast cancer.
    Modig H, Borgström S, Nilsson I, Westman G.
    J Steroid Biochem; 1990 Jun 22; 36(3):237-8. PubMed ID: 2142243
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Phase II study of high dose toremifene in advanced breast cancer progressing during tamoxifene treatment.
    Jönsson PE, Malmberg M, Bergljung L, Ingvar C, Ericsson M, Ryden S, Nilsson I, Terje IJ.
    Anticancer Res; 1991 Jun 22; 11(2):873-5. PubMed ID: 1829600
    [Abstract] [Full Text] [Related]

  • 10. Phase II experience with toremifene in the treatment of ER-positive breast cancer of postmenopausal women.
    Valavaara R.
    Cancer Invest; 1990 Jun 22; 8(2):275-6. PubMed ID: 2144787
    [No Abstract] [Full Text] [Related]

  • 11. Predictive value of tumor estrogen and progesterone receptor levels in postmenopausal women with advanced breast cancer treated with toremifene.
    Valavaara R, Tuominen J, Johansson R.
    Cancer; 1990 Dec 01; 66(11):2264-9. PubMed ID: 2147123
    [Abstract] [Full Text] [Related]

  • 12. The significance of estrogen receptors in tamoxifen and toremifene therapy.
    Valavaara R, Kangas L.
    Ann Clin Res; 1988 Dec 01; 20(5):380-8. PubMed ID: 2975479
    [Abstract] [Full Text] [Related]

  • 13. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer.
    Saarto T, Blomqvist C, Ehnholm C, Taskinen MR, Elomaa I.
    J Clin Oncol; 1996 Feb 01; 14(2):429-33. PubMed ID: 8636753
    [Abstract] [Full Text] [Related]

  • 14. Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer.
    Bishop J, Murray R, Webster L, Pitt P, Stokes K, Fennessy A, Olver I, Leber G.
    Cancer Chemother Pharmacol; 1992 Feb 01; 30(3):174-8. PubMed ID: 1385761
    [Abstract] [Full Text] [Related]

  • 15. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Eastern European Study Group.
    Gershanovich M, Garin A, Baltina D, Kurvet A, Kangas L, Ellmén J.
    Breast Cancer Res Treat; 1997 Sep 01; 45(3):251-62. PubMed ID: 9386869
    [Abstract] [Full Text] [Related]

  • 16. High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer. An ongoing phase II multicenter Finnish-Latvian cooperative study.
    Hietanen T, Baltina D, Johansson R, Numminen S, Hakala T, Helle L, Valavaara R.
    Breast Cancer Res Treat; 1990 Aug 01; 16 Suppl():S37-40. PubMed ID: 2149284
    [Abstract] [Full Text] [Related]

  • 17. Dose-dependent hormonal effects of toremifene in postmenopausal breast cancer patients.
    Ellmén J, Werner D, Hakulinen P, Keiling R, Fargeot P, Falkson G, Bezwoda WR.
    Cancer Chemother Pharmacol; 2000 Aug 01; 45(5):402-8. PubMed ID: 10803924
    [Abstract] [Full Text] [Related]

  • 18. Antiestrogenic treatment of advanced and recurrent carcinoma corporis uteri--a phase II study of toremifene.
    Horvath G, Stendahl U, Kalling M, Fernö M, Himmelmann A, Hajba A.
    Anticancer Res; 1990 Aug 01; 10(2A):323-5. PubMed ID: 2140668
    [Abstract] [Full Text] [Related]

  • 19. Toremifene in postmenopausal breast cancer. Efficacy, safety and cost.
    Mäenpää JU, Ala-Fossi SL.
    Drugs Aging; 1997 Oct 01; 11(4):261-70. PubMed ID: 9342556
    [Abstract] [Full Text] [Related]

  • 20. A phase I trial of toremifene, a new antiestrogen.
    Hamm JT.
    Cancer Invest; 1990 Oct 01; 8(2):273-4. PubMed ID: 2144786
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.